The patents — one each in Hong Kong and the US and a couple in India — are valid through 2032, 2030 and 2034.
“The granted claims of the patents include the class of selective H3 and 5-HT 6 compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia” the company said.
CEO Venkat Jasti the patents are for the company’s pipeline of molecules in central nervous system area that are being developed for “cognitive disorders with high unmet medical need with huge market potential globally.”
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products.
Suven has 4 clinical stage compounds, a Phase 2 undergoing SUVN-502, Phase 2 ready SUVN-G3031, Phase 1 completed SUVN-D4010 and Phase 1 commenced SUVN-911.
In addition to these clinical compounds, the Company has nine discovered therapeutic drug candidates currently in various stages of pre-clinical development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and pain.
The patent numbers for the new compounds in India are 287865 and 289092, and 9802896 in the USA.